Text Size

Tear concentration and safety of levofloxacin ophthalmic solution 1.5% compared with ofloxacin ophthalmic solution 0.3% after topical administration in healthy adult volunteers

Walters T., Rinehart M., Krebs W., Holdbrook M.


  • 2010
  • Cornea
View publication
  • Therapeutic Area

    Front of the eye (FOTE)

  • Categories

    Clinical development

  • Affiliations

    Keystone Research, Ltd., 5717 Balcones Drive, Austin, TX 78731, United States; Santen Inc., Napa, CA, United States

Related Publications

Efficacy and Tolerance of Nova22007 Versus Vehicle in Patients With Vernal Keratoconjunctivitis (NOVATIVE): A Phase II/III, Multicenter, Double-masked, Randomized Study of 0.05% Cyclosporine A and 0.1% Ophthalmic Cationic Emulsion Versus Vehicle in Patients With Vernal Keratoconjunctivitis

Leonardi A, Pisella PJ, Benítez-Del-Castillo JM, Amrane M, Ismail D, Doan S, Bremond-Gignac D.


Correlation between gene expression and clinical scores in vernal keratoconjunctivitis

Leonardi A, Cavarzeran F, Rosani U, Righetti G, Garrigue JS, Brun P.


Topical cyclosporine A cationic ophthalmic emulsion in paediatric vernal keratoconjunctivitis: pooled analysis of randomised NOVATIVE and VEKTIS trials

Leonardi A, Doan S, Aragona P,  Amrane M, Ismail D, Montero J, Németh J, Bremond-Gignac D


Can't find what you're looking for?

Contact us

Document number: NP-No product-EMEA-0110
Date of preparation: February 2022